A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
01/2012
01/03/2012	CA2266332C Antibodies against human parathyroid hormone related protein
01/03/2012	CA2261346C Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases
01/03/2012	CA2260855C Polynucleotide vaccine formula in particular against bovine respiratory pathology
01/03/2012	CA2242414C Anti-cd18 antibodies for use against stroke
01/03/2012	CA2236591C Continuous low-dose cytokine infusion therapy
01/03/2012	CA2227265C Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
01/03/2012	CA2226973C Modulators of the function of fas receptors and other proteins
01/03/2012	CA2215483C Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same
01/02/2012	DE202011103324U1 Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten Therapeutic anti-TIRC7 antibodies for use in immune and other diseases
12/2011
12/29/2011	WO2011163669A2 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
12/29/2011	WO2011163628A2 Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
12/29/2011	WO2011163593A2 Induction of immune response
12/29/2011	WO2011163568A1 Conjugates comprising an n-oxime bond and associated methods
12/29/2011	WO2011163539A2 nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD)
12/29/2011	WO2011163478A2 Dual variable domain immunoglobulins and uses thereof
12/29/2011	WO2011163458A2 Compositions and methods for stabilizing protein-containing formulations
12/29/2011	WO2011163452A2 Treating surface of the eye disorders
12/29/2011	WO2011163446A2 Pan-lyssavirus vaccines against rabies
12/29/2011	WO2011163412A1 Antibodies to the c3d fragment of complement component 3
12/29/2011	WO2011163308A2 Compositions and methods for preventing and treating organ injury and/or dysfunction
12/29/2011	WO2011162933A1 Anti-integrin immunoconjugate dosing regimens
12/29/2011	WO2011162639A1 Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon
12/29/2011	WO2011161970A1 Anti-pdgf receptor antibody
12/29/2011	WO2011161653A1 Combinations of meningococcal factor h binding proteins
12/29/2011	WO2011161630A1 Highly specific antibodies, composition and methods thereof
12/29/2011	WO2011161263A1 Pharmaceutical compositions for cutaneous administration
12/29/2011	WO2011161244A1 Homodimeric protein constructs
12/29/2011	WO2011161226A2 Novel antibody formulation
12/29/2011	WO2011161189A1 Anti-hepsin antibodies and methods of use
12/29/2011	WO2011160859A1 Antibody derivatives
12/29/2011	WO2011160845A2 Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
12/29/2011	WO2011160563A1 Novel porcine interferon and use thereof
12/29/2011	WO2011160429A1 Anti-p185（her2/erbb2）humanized antibodies
12/29/2011	WO2011160182A1 Means of controlling infection persistence of helicobacter pylori
12/29/2011	WO2011160177A1 Constrained immunogenic compositions and uses therefor
12/29/2011	WO2011139368A3 Methods of treatment of inflammatory diseases
12/29/2011	WO2011138557A3 Use of an anti-cd71 antibody for preparing a medicament
12/29/2011	WO2011130652A3 Compositions and methods for vaccinating humans and animals against enveloped viruses
12/29/2011	WO2011127924A3 Agent for use in the topical or local treatment of cervical dysplasias
12/29/2011	WO2011121576A3 Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
12/29/2011	WO2011113041A3 Neutralization of flt3 ligand as a leukemia therapy
12/29/2011	WO2011109729A9 Ep1 inhibition
12/29/2011	WO2011103458A3 Compositions and methods for using and identifying antimicrobial agents
12/29/2011	WO2011103389A9 Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
12/29/2011	WO2011100508A3 Methods and compositions related to glycoprotein-immunoglobulin fusions
12/29/2011	WO2011100468A3 Methods and materials for treating cancer
12/29/2011	WO2011097573A3 Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
12/29/2011	WO2011097500A3 The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
12/29/2011	WO2011091366A3 Methods of treating or preventing periodontitis and diseases associated with periodontitis
12/29/2011	WO2011090973A3 Immunotherapy compositions and methods of treatment
12/29/2011	WO2011084090A3 Method for preventing infectious diseases of plants, animals and humans
12/29/2011	WO2011008863A3 Stereoisomer peptides and their polymer conjugates for hiv disease
12/29/2011	WO2010142030A8 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
12/29/2011	WO2010065921A3 Antibody design using anti-lipid antibody crystal structures
12/29/2011	US20110319869 Human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
12/29/2011	US20110319599 MN Gene and Protein
12/29/2011	US20110319590 Tumour Cell Lines and Uses Thereof
12/29/2011	US20110319480 Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens
12/29/2011	US20110318834 Multiple-tumor aberrant growth genes
12/29/2011	US20110318832 Human Telomerase Catalytic Subunit
12/29/2011	US20110318421 Surface functionalized ceramic nanoparticles
12/29/2011	US20110318416 Bioresorbable polymer matrices and methods of making and using the same
12/29/2011	US20110318408 Hla class i a2 tumor associated antigen peptides and vaccine compositions
12/29/2011	US20110318407 Inactivated dengue virus vaccine with aluminium-free adjuvant
12/29/2011	US20110318387 Immunization method using cancer cells
12/29/2011	US20110318386 Bacillus isolates and methods of their use to protect against plant pathogens
12/29/2011	US20110318385 Engineered botulinum neurotoxin c1 with selective substrate specificity
12/29/2011	US20110318384 Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant lactobacillus transformed by the same
12/29/2011	US20110318383 Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
12/29/2011	US20110318382 Immunomodulatory agents and methods of use
12/29/2011	US20110318381 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
12/29/2011	US20110318380 MHC Multimers in Cancer Vaccines and Immune Monitoring
12/29/2011	US20110318379 Vaccine for Porcine Post-Weaning Diarrhea Caused by Enterotoxigenic Escherichia Coli
12/29/2011	US20110318378 Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use
12/29/2011	US20110318377 Methylated TAT Polypeptides and Methods of Use Thereof
12/29/2011	US20110318376 Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
12/29/2011	US20110318375 Immunomodulatory Therapeutic Agents
12/29/2011	US20110318374 Spanx-b polypeptides and their use
12/29/2011	US20110318373 Immunosuppression modulating compounds
12/29/2011	US20110318372 Indoleamine 2,3-dioxygenase based immunotherapy
12/29/2011	US20110318371 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
12/29/2011	US20110318370 Cxcl4l1 as a biomarker of pancreatic cancer
12/29/2011	US20110318369 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
12/29/2011	US20110318368 Anti-human alpha9 integrin antibody and use thereof
12/29/2011	US20110318367 Novel targets for treatment of hypercholesterolemia
12/29/2011	US20110318366 Biologic compounds
12/29/2011	US20110318365 Methods for treatment of degenerative disease associated with apoptosis
12/29/2011	US20110318364 nonapeptide with anti-tumour activity
12/29/2011	US20110318363 Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
12/29/2011	US20110318362 Novel card proteins involved in cell death regulation
12/29/2011	US20110318361 Anticancer Drug Comprising Inhibitor of Tmprss4
12/29/2011	US20110318360 Anti-lipid antibodies
12/29/2011	US20110318359 Method for reducing blood pressure using inhibitors of plasma kallikrein
12/29/2011	US20110318358 Immunotherapy for clearing pathological tau conformers
12/29/2011	US20110318357 Methods and compositions based on shiga toxin type 2 protein
12/29/2011	US20110318356 Antibodies Against Tissue Factor Pathway Inhibitor
12/29/2011	US20110318355 Mutant proteins of the f protein of piv-5 and piv-2
12/29/2011	US20110318354 Cytokine receptor zcytor17 multimers
12/29/2011	US20110318353 Humanized IL-25 Antibodies
12/29/2011	US20110318352 Compositions and methods for the treatment of viral infections

1 ... 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 ... 1823